open access

Vol 20, No 2 (2015)
Original research articles
Published online: 2015-03-01
Submitted: 2014-02-04
Get Citation

Influence of C-choline PET/CT on radiotherapy planning in prostate cancer

Escarlata López, Antonio Lazo, Antonio Gutiérrez, Gregorio Arregui, Isabel Núñez, Antonio Sacchetti
DOI: 10.1016/j.rpor.2014.11.008
·
Rep Pract Oncol Radiother 2015;20(2):104-112.

open access

Vol 20, No 2 (2015)
Original research articles
Published online: 2015-03-01
Submitted: 2014-02-04

Abstract

Aim

To evaluate the influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer patients.

Background

Precise information on the extension of prostate cancer is crucial for the choice of an appropriate therapeutic strategy.

11C-choline positron emission tomography (11C-choline PET/CT) has two roles in radiation oncology (RT): (1) patient selection for treatment and (2) target volume selection and delineation.

In conjunction with high-accuracy techniques, it might offer an opportunity of dose escalation and better tumour control while sparing healthy tissues.

Materials and methods

We carried out a retrospective study in order to analyse RT planning modification based on 11C-choline PET/CT in 16 prostate cancer patients. Patients were treated with hypofractionated step-and-shoot Intensity Modulated Radiotherapy (IMRT), or Volumetric Modulated Arc Therapy (VMAT), and a daily cone-beam CT for Image Guided Radiation Therapy (IGRT). All patients underwent a 11C-choline-PET/CT scan prior to radiotherapy.

Results

In 37.5% of cases, a re-delineation and new dose prescription occurred. Data show good preliminary clinical results in terms of biochemical control and toxicity. No gastrointestinal (GI)/genitourinary (GU) grade III toxicities were observed after a median follow-up of 9.5 months.

Conclusions

In our experience, concerning the treatment of prostate cancer (PCa), 11C-choline PET/CT may be helpful in radiotherapy planning, either for dose escalation or exclusion of selected sites.

Abstract

Aim

To evaluate the influence of 11C-choline PET/CT on radiotherapy planning in prostate cancer patients.

Background

Precise information on the extension of prostate cancer is crucial for the choice of an appropriate therapeutic strategy.

11C-choline positron emission tomography (11C-choline PET/CT) has two roles in radiation oncology (RT): (1) patient selection for treatment and (2) target volume selection and delineation.

In conjunction with high-accuracy techniques, it might offer an opportunity of dose escalation and better tumour control while sparing healthy tissues.

Materials and methods

We carried out a retrospective study in order to analyse RT planning modification based on 11C-choline PET/CT in 16 prostate cancer patients. Patients were treated with hypofractionated step-and-shoot Intensity Modulated Radiotherapy (IMRT), or Volumetric Modulated Arc Therapy (VMAT), and a daily cone-beam CT for Image Guided Radiation Therapy (IGRT). All patients underwent a 11C-choline-PET/CT scan prior to radiotherapy.

Results

In 37.5% of cases, a re-delineation and new dose prescription occurred. Data show good preliminary clinical results in terms of biochemical control and toxicity. No gastrointestinal (GI)/genitourinary (GU) grade III toxicities were observed after a median follow-up of 9.5 months.

Conclusions

In our experience, concerning the treatment of prostate cancer (PCa), 11C-choline PET/CT may be helpful in radiotherapy planning, either for dose escalation or exclusion of selected sites.

Get Citation

Keywords

Prostate cancer; [[ce:sup loc=" pre" ]]11C-choline PET/CT; Radiotherapy planning

About this article
Title

Influence of C-choline PET/CT on radiotherapy planning in prostate cancer

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 20, No 2 (2015)

Pages

104-112

Published online

2015-03-01

DOI

10.1016/j.rpor.2014.11.008

Bibliographic record

Rep Pract Oncol Radiother 2015;20(2):104-112.

Keywords

Prostate cancer
[[ce:sup loc="pre"]]11C-choline PET/CT
Radiotherapy planning

Authors

Escarlata López
Antonio Lazo
Antonio Gutiérrez
Gregorio Arregui
Isabel Núñez
Antonio Sacchetti

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl